Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.
Nicola J ManeyHenrique LemosBen Barron-MillarChristopher CareyIan HerronAmy E AndersonAndrew L MellorJohn D IsaacsArthur G PrattPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Our findings indicate that Pim kinases are plausible therapeutic targets in a readily identifiable subgroup of patients with early RA. Repurposing of Pim inhibitors for this disease should be considered.